medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2003, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2003; 48 (2)

Thrombolysis with recombinant tissue plasminogen for cerebral vascular episode in a patient with a Bjork-Shiley aortic prosthesis valve

León M, Gloss G, Lijtszain C, Zambito BGF, Domínguez GLR

Language: Spanish
References: 22
Page: 118-123
PDF size: 53.82 Kb.


ABSTRACT

Stroke is a leading cause of death in young persons and adults when it is associated with a mechanical heart valve prosthesis, the risk is even higher. Thrombolytic agents are a particular choice of therapy when cardioembolism is documented. The aim is reestablish the cerebral blood flow and recovery of the neurological function, “time is Brain”. We present the case of a 45 years old male with an aortic Bjork-Shiley prosthesis who came to the hospital with an ischemic stroke due to cardioembolism. He was treated with r-TPA successfully and without complications. It is important to warning and notice all patients with a Bjork-Shiley prosthesis because the risk of rupture of the strut.


REFERENCES

  1. Catherine M. Otto, Valvular heart disease. Philadelphia, PA: WB Saunders, 1999: 380-416.

  2. Loscalzo J, Braunwald E. Tissue plasminogen activator. New Engl J Med 1988; 319 (14): 925-930.

  3. Edmunds LH. Thromboembolic complic of current cardiac valvular prosthesis. Ann Thorac Surg 1982; 34: 96-106.

  4. Shim EB, Chang K. Numerical analysis on three dimensional Bjork-Shiley valvular flow in aorta. J Biochem Engl 1997; 119 (1): 45-51.

  5. Valla J, Corbineau H, Sevray B et al. Long term results over 20 years of aortic valve replacement with the standard Bjork-Shiley prosthesis. Arch Mal Coeur Vaiss 1996; 89 (9): 1137-1143.

  6. Koornneef F, Van Gaalen G, De Mol B. A risk assessment and control model for the failing Bjork-Shiley convexo-concave heart valve. Int J Technol Asses Health Care 1996; 12 (1): 141-145.

  7. Zeumer H, Freitag H, Zanella F. Local intra-arterial fibrinolytic therapy in patients with stroke. Urokinase versus r-TPA. Neuroradiology 1993; 35: 159-162.

  8. Roberts R, Kleinman N. Earlier diagnosis and treatment of acute infarction necessitates the need for a new diagnosis mind-set. Circulation 1994; 89 (2): 872-881.

  9. Hacke W, Kaste M, Fiechi C. Intravenous thrombolysis with recombinant tissue plasminogen active for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 271 (13): 1017-1025.

  10. The National Institute of Neurological Disorders and stroke r-TPA study group tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.

  11. Tomsick T, Brott T, Barsan W. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. Am J Neuroradiol 1996; 17: 79-85.

  12. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998; 352: 1245-1251.

  13. Gunnar R, Bourdillon P, Dixon D. ACC-AHA guidelines for the early management of patients with acute myocardial infarction. Circulation 1990; 82: 664-707.

  14. Brott T, Haley E, Levy D. Urgent therapy for stroke II: pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-645.

  15. Levy D, Brott T, Haley E. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25: 291-297.

  16. Marler J. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 1995; 333 (24): 1581-1587.

  17. Brott T, Haley C, Levy D. Pilot study of tissue plasminogen activator administrated within 90 minutes. Stroke 1992; 23: 632-640.

  18. Dos Santos F, Junior T, Caramelli B. The influence of lipoprotein a in thrombolysis with r-TPA for myocardial infarction. Arq Bras Cardiol 1991; 57 (1): 9-12.

  19. Del Zoppo G. Acute stroke on the threshold of a therapy? New Engl J Med 1995; 333 (13): 1632-1633.

  20. Chiu D, Krieger D, Villar-Cordova C, Kasner SE, Morgenstern LB et al. Intravenous tissue plasminogen activator for acute ischemic stroke feasibility, safety and efficacy in the first year of clinical practice. Stroke 1998; 29: 18-22.

  21. Gladstone DJ, Black SE. Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice. CMAJ 2001; 165 (3): 311-317.

  22. NINDS r-TPA Stroke Study Group. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 2000; 31 (12): 2912-2919.




2020     |     www.medigraphic.com